Reset filter
Mots-clés
artritida revmatoidní ×
Afficher plus Mots-clés
Table des matières
  1. 1. Essai clinique
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

243 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

dbGaP phs000944 eMERGE Clinical Center at Partners HealthCare - Eligibility

- 27/11/2024 - 6 Formulaires, 2 Groupes Item, 11 Eléments de données, 1 Langue
Groupes Item: IG.elig, IG.elig
Principal Investigator: Scott T. Weiss, MD, MS, Partners HealthCare System, Boston, MA, USA MeSH: Hypercholesterolemia,Asthma,Arthritis, Rheumatoid,Attention Deficit Disorder with Hyperactivity,Bipolar Disorder,Coronary Disease,Depression,Heart Failure,Inflammatory Bowel Diseases,Multiple Sclerosis,Schizophrenia,Stroke https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000944 The Partners HealthCare Biobank is a large research data and sample repository working within the framework of Partners Personalized Medicine. It provides researchers access to high quality, consented samples to help foster research, advance understanding of the causes of common diseases, and advance the practice of medicine. The Partners Biobank provides banked samples (plasma, serum and DNA) collected from consented patients. These samples are available for distribution to Partners HealthCare investigators with appropriate approval from the Partners Institutional Review board (IRB). They are linked to clinical data that originates in the Electronic Medical Record (EMR), as well as additional health information collected in a self-reported survey. The Partners Biobank will be genotyping 25,000 subjects with the Illumina Multiethnic Beadchip 1.6 million SNPs with exome and custom content ( 60,000 LoFs). Of the participants genotyped so far, 4929 of 4962 (99.3%) individuals have genotype data that passed the default quality thresholds for the Infinium array (call rate = 0.99). We are submitting the genotype data to dbGaP for 4929 subjects with 12 phenotypes (based on icd9 codes). We will do annual releases until we reach the full 25,000 genotyped subjects.

pht004847.v1.p1

1 Groupe Item 5 Eléments de données

pht005288.v1.p1

1 Groupe Item 6 Eléments de données

pht004844.v1.p1

1 Groupe Item 2 Eléments de données

pht004845.v1.p1

1 Groupe Item 3 Eléments de données

pht004846.v1.p1

1 Groupe Item 18 Eléments de données

dbGaP phs000983 Pharmacogenomics of Rheumatoid Arthritis Therapy - Eligibility

- 01/12/2023 - 5 Formulaires, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: IG.elig
Principal Investigator: Rex Chisholm, PhD, Northwestern University MeSH: Arthritis, Rheumatoid https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000983 Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis worldwide and affects 1.3 million adults in the USA. It has previously been studied using phenotype algorithms to identify electronic health records (EHR) case cohorts. Early genetic studies of EHR-linked cohorts of RA patients have been replicated in known associations. Further development of collections of EHR-linked cohorts for RA and other phenotypes may enable not only enhanced understanding of disease risks but also the investigation of outcomes and treatment responses.

pht005005.v1.p1

1 Groupe Item 5 Eléments de données

pht005007.v1.p1

1 Groupe Item 5 Eléments de données

pht005004.v1.p1

1 Groupe Item 5 Eléments de données

pht005006.v1.p1

1 Groupe Item 7 Eléments de données

dbGaP phs001340 Identification and Targeting of Inflammatory Macrophage-Fibroblast Crosstalk in Rheumatoid Arthritis - pht009154.v1.p1

- 02/03/2023 - 4 Formulaires, 1 Groupe Item, 2 Eléments de données, 1 Langue
Groupe Item: pht009154
Principal Investigator: Laura T. Donlin, PhD, Hospital for Special Surgery, New York, NY, USA MeSH: Arthritis, Rheumatoid,Arthritis https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001340 Macrophages tailor their function according to the signals found in tissue microenvironments, assuming a wide spectrum of phenotypes. A detailed understanding of macrophage phenotypes in human tissues is limited. Using single-cell RNA sequencing, we defined distinct macrophage subsets in the joints of patients with the autoimmune disease rheumatoid arthritis (RA), which affects ~1% of the population. The subset we refer to as HBEGF+ inflammatory macrophages is enriched in RA tissues and is shaped by resident fibroblasts and the cytokine tumor necrosis factor (TNF). These macrophages promoted fibroblast invasiveness in an epidermal growth factor receptor-dependent manner, indicating that intercellular cross-talk in this inflamed setting reshapes both cell types and contributes to fibroblast-mediated joint destruction. In an ex vivo synovial tissue assay, most medications used to treat RA patients targeted HBEGF+ inflammatory macrophages; however, in some cases, redirecting them into a state is not expected to resolve inflammation. These data highlight how advances in our understanding of chronically inflamed human tissues and the effects of medications therein can be achieved by studies on local macrophage phenotypes and intercellular interactions. Reprinted from Kuo, Ding et al., Science Translational Medicine 2019, PMID: 31068444, with permission from American Association for the Advancement of Science.

pht009155.v1.p1

1 Groupe Item 2 Eléments de données

pht009156.v1.p1

1 Groupe Item 2 Eléments de données

pht009157.v1.p1

1 Groupe Item 6 Eléments de données

dbGaP phs001360 Genome-Wide Association Study in African-Americans with RA - Eligibility

- 28/02/2023 - 5 Formulaires, 1 Groupe Item, 10 Eléments de données, 1 Langue
Groupe Item: IG.elig
Principal Investigator: S. Louis Bridges, Jr., MD, PhD, University of Alabama at Birmingham, Birmingham, AL, USA MeSH: Arthritis, Rheumatoid https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001360 The Consortium for the Longitudinal Evaluation of African-Americans with Early Rheumatoid Arthritis (*CLEAR*) Registry and Repository, supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (*NIAMS*), was established in 2000 to provide a resource for the scientific community to explore genetic and non-genetic factors affecting rheumatoid arthritis (*RA*) occurrence and outcomes in African Americans. The long term objective is a database and a repository of 1,100 RA and 550 matched healthy African-American subjects. This CLEAR Registry and Repository has two arms: a longitudinal arm for subjects with early RA (enrollment from 2000 to 2005) and a cross-sectional arm for subjects with any disease duration (enrollment from 2006 to 2012). CLEAR has two components: a database and a repository. The database contains extensive demographic, socioeconomic, clinical and radiographic (radiographs of hands and feet) information and bone mineral density data from DEXA scans. The repository contains genomic DNA, plasma and serum on most of the participants. Participants in CLEAR II had RNA isolated from peripheral blood cells.

pht006293.v1.p1

1 Groupe Item 4 Eléments de données

pht006296.v1.p1

1 Groupe Item 5 Eléments de données

pht006294.v1.p1

1 Groupe Item 3 Eléments de données

pht006295.v1.p1

1 Groupe Item 14 Eléments de données

dbGaP phs001371 Inflammation-Induced Stabilization of mRNA in Rheumatoid Arthritis - pht006544.v1.p1

- 25/02/2023 - 3 Formulaires, 1 Groupe Item, 2 Eléments de données, 1 Langue
Groupe Item: pht006544
Principal Investigator: Lionel B. Ivashkiv, MD, Hospital for Special Surgery, New York, NY, USA MeSH: Arthritis, Rheumatoid,Arthritis https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001371 During rheumatoid arthritis (RA), TNF activates fibroblast-like synoviocytes (FLS) inducing in a temporal order a constellation of genes, which perpetuate synovial inflammation. Although the molecular mechanisms regulating TNF-induced transcription are well characterized, little is known about the impact of mRNA stability on gene expression and the impact of TNF on decay rates of mRNA transcripts in FLS. To address these issues we performed RNA sequencing and genome-wide analysis of the mRNA stabilome in RA FLS. We found that TNF induces a biphasic gene expression program: initially, the inducible transcriptome consists primarily of unstable transcripts but progressively switches and becomes dominated by very stable transcripts. This temporal switch is due to: a) TNF-induced prolonged stabilization of previously unstable transcripts that enables progressive transcript accumulation over days and b) sustained expression and late induction of very stable transcripts. TNF- induced mRNA stabilization in RA FLS occurs during the late phase of TNF response, is MAPK-dependent, and involves several genes with pathogenic potential such as IL6, CXCL1, CXCL3, CXCL8/IL8, CCL2, and PTGS2. These results provide the first insights into genome-wide regulation of mRNA stability in RA FLS and highlight the potential contribution of dynamic regulation of the mRNA stabilome by TNF to chronic synovitis.

pht006545.v1.p1

1 Groupe Item 3 Eléments de données

pht006546.v1.p1

1 Groupe Item 6 Eléments de données

Eligibility Rheumatoid Arthritis NCT00650078

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 14 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT00650078

Eligibility Rheumatoid Arthritis NCT00162201

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 13 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00162201

Eligibility Rheumatoid Arthritis NCT01745055

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 6 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Co-Administration Of Methotrexate And CP-690,550; ODM derived from: https://clinicaltrials.gov/show/NCT01745055

Eligibility Severe Knee Pain NCT02255383

- 18/09/2021 - 1 Formulaire, 2 Groupes Item, 18 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Persona Total Knee Arthroplasty Outcomes Study; ODM derived from: https://clinicaltrials.gov/show/NCT02255383

Eligibility NCT00502840 Rheumatoid Arthritis - Eligibility

- 17/09/2021 - 1 Formulaire, 2 Groupes Item, 6 Eléments de données, 2 Langues
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00502840

Eligibility NCT00754559 Rheumatoid Arthritis - Eligibility

- 17/09/2021 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 2 Langues
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00754559

Eligibility Primary Sjogren's Syndrome NCT02027298

- 28/07/2021 - 1 Formulaire, 2 Groupes Item, 18 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study; ODM derived from: https://clinicaltrials.gov/show/NCT02027298

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial